AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00915759 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProKera
Description: ProKera placed in non-dominant eye after PRK
Study NCT01969513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PROCEDURE: EPLEY MANOEUVRE
Description: The procedure involves a series of four movements of the head and body from sitting to lying, rolling over and back to sitting.
Study NCT01969513 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PROCEDURE: SHAM MANOEUVRE
Description: Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
Study NCT01041404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
Study NCT01041404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
Study NCT01041404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
Study NCT01041404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
Study NCT01041404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
Study NCT01041404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
Study NCT01041404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
Study NCT02500277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprobe pleural biopsy first
Description: Four pleural biopsy specimens will be obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm) followed by 6-10 pleural biopsy specimens obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter).
Study NCT02500277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible forceps biopsy first
Description: Six to ten pleural biopsy specimens will be obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter) followed by four pleural biopsy specimens obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm)
Study NCT03497611 — intervention group
Intervention type: PROCEDURE
Intervention: transcatheter valve implantation
Description: aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
Study NCT00567957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
Study NCT00567957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: same volume iv bolus before induction followed by same volume infusion
Study NCT00748865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Ultra Lubricant Eye Drops
Description: Systane Ultra Lubricant Eye Drops 1 drop each eye one time
Study NCT00748865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Lubricant Eye Drops
Description: Systane Lubricant Eye Drops 1 drop each eye one time
Study NCT02439736 — intervention group
Intervention type: OTHER
Intervention: Blood draw within 12 hours of head injury
Study NCT01251822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350 plus electrolytes
Description: Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.
Study NCT01251822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: Patients less than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by two prucalopride 1 mg tablets for 28 days.~Patients more than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by one prucalopride 1 mg tablet and one placebo tablet for 28 days.
Study NCT02098005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care evidence-based physiotherapy
Description: Arm 1 (i.e., the control group) will be subjected to a control intervention, including back/neck school and general exercises. 3 sessions of education (session 1: group session; session 2: online module; session 3: individual session) will be given by a physiotherapist, followed by 15 sessions of traditional physiotherapy and general exercises. The 18 sessions will be spread over a period of 3 months.
Study NCT02098005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modern neuroscience approach
Description: Arm 2 (i.e., the experimental group) will receive pain neuroscience education (3 sessions of education), followed by 15 sessions of cognition-targeted motor control training (15 sessions). The 18 sessions will be spread over a period of 3 months.
Study NCT04253808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted, high-fat diet
Description: Diet composition was \~45% fats, \~30% carbohydrates, and \~25% proteins. Calorie needs were provided according to what the Bioelectrical Impedance (BIA) device gave as required to maintain bodyweight.~Sources of macronutrients:~* Carbohydrates: from whole grains, dairy products, legumes, fruits, and vegetables.~* Fats: from mono- and polyunsaturated fatty acids, including medium- and long-chain fatty acids.~* Proteins: plant-based proteins and lean animal-based proteins. All meals were provided to the participants throughout the study period and the diet was provided orally unless the patient was on a feeding tube or a feeding tube is ordered by a physician during the study period. Diet texture was according to patients chewing and swallowing abilities. If the patient is on a feeding tube or intake is insufficient, a formula with similar macronutrient composition + a protein supplement was provided.
Study NCT04253808 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular composition diet
Description: The regular composition diet contained approximately 50-52% carbohydrates, 30% fats, and 18-20% proteins
Study NCT00415545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid Watchers LITE Educational Intervention
Description: Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.
Study NCT00415545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid Watchers PLUS Educational Intervention
Description: Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
Study NCT02776852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: SR15-43-Y65-158)
Study NCT02201667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180-mg loading dose followed by 90mg twice daily for 30 days
Study NCT02201667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: 300-mg loading dose followed by 75mg once daily for 30 days.
Study NCT02201667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 300mg loading dose aspirin and followed by 100mg once daily
Study NCT02201667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 300mg loading dose aspirin and followed by 100mg once daily
Study NCT02201667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
Study NCT02201667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
Study NCT00714337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).
Study NCT00714337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: One single oral dose of 90mg (3 x 30mg AZD1386 capsules)
Study NCT00714337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: One single oral dose of 90mg (6 x 15mg AZD1386 tablets)
Study NCT02452749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardiovascular health dietary supplement
Description: Herbal/mineral dietary supplement
Study NCT02152449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation
Study NCT02324868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shower patch IV catheter protection
Description: Shower patch will be available for the patient for bathing activities
Study NCT02324868 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional IV catheter protection
Description: No Shower patch will be provided during study period
Study NCT04675697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-etoposide+Anlotinib
Description: Platinum-etoposide regiment consisted of etoposide 100mg/m2, d1\~3 of 21-day cycle, with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5\~6, Q3W). Anlotinib treated of 12mg Qd from day 1 to 14 of a 21-day cycle. Eligible patients received anlotinib plus platinum-etoposide for 4\~6 cycles, and followed by maintenance therapy with Anlotinib. The efficacy was evaluated every 6 weeks (2 cycles) through treatment.
Study NCT02189304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT010
Description: PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
Study NCT02189304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PT010
Description: PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
Study NCT02189304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT009
Description: PT009 administered as 2 inhalations
Study NCT00915759 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bandage contact lens
Description: Bandage contact lens placed in dominant eye, the current standard after PRK
Study NCT04769271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing
Description: Supra- and sub-gingival calculus and debris were removed
Study NCT04769271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing with tea tree oil
Description: Supra- and sub-gingival calculus and debris were removed and 5% tea tree oil was applied
Study NCT01765036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue®
Description: An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
Study NCT04329728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVM0703
Description: Intravenous infusion over \~1 hours
Study NCT01225133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex Ayurvedic Treatment
Description: In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
Study NCT01225133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
Study NCT01604525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Web
Description: The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
Study NCT01604525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Coaching
Description: Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
Study NCT01604525 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Untailored Web
Description: Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
Study NCT03335904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxic Hypercapnic Ventilatory Response Test
Description: End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
Study NCT03335904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyperoxic Hypercapnic Ventilatory Response Test
Description: End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
Study NCT03335904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic Hypercapnic Ventilatory Response Test
Description: End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
Study NCT03335904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxic Hypercapnic Ventilatory Response Test
Description: End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
Study NCT03335904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated Hypoxic Apneas
Description: Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.
Study NCT03335904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Repeated Hypoxic Apneas
Description: Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.
Study NCT03335904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic Sleep Study
Description: Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.
Study NCT03335904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxic Sleep Study
Description: Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.
Study NCT03335904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan, 50mg, BID
Study NCT03335904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 50mg, BID
Study NCT04031248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: In this study an axial vibratory platform will be used: POWER-PLATE pro 5 AIRdaptive TM HP®. This device is reviewed annually by the technical unit of the company itself and complies with the international regulations that regulate the Medical Devices \[Devices Directive (MDD) 93/42 / EEC (ISO 2631. 2011, Powerplate.com, 2013)\]. The vibration will be administered with 2 mm of amplitude and 40 Hz of frequency.
Study NCT04031248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EXERCISE group
Description: The program will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work. The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience.
Study NCT02466425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465
Description: 12.5mg and 25mg capsules (one capsule daily)
Study NCT02466425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule that appear identical in size, weight, shape, color
Study NCT00470262 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fenofibrate 145mg PO QD
Description: Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
Study NCT00470262 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pioglitazone 45 mg PO QD
Description: Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
Study NCT01760499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PV-10
Description: PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
Study NCT01760499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
Study NCT02189304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PT009
Description: PT009 administered as 2 inhalations
Study NCT02189304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler
Description: Symbicort Turbohaler taken as 2 inhalations
Study NCT03174561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Inuline, Choline and Silymarin
Description: Combination of one sachet: Inuline (5000 mg), Silybum marianum seed extract (50 mg), Choline (37 mg) The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days. Diet restriction is consider together with dietary supplement intake.
Study NCT03638674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DXA + CT
Description: Two dual-energy X-ray scans + CT scan
Study NCT05088434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anaerobically Cultivated Human Intestinal Microbiota (ACHIM)
Description: One vial of ACHIM suspension (ACHIM Biotherapeutics AB, Vallingby, Sweden), containing 30 x 109 colony forming unit (CFU) of bacteria, was given through the work channel of a gastroscope into the lower part of duodenum.
Study NCT05088434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Donor fecal microbiota transplantation
Description: Only 60 ml of sterile 0.9% normal saline were added to a stool specimen, collected from the respective donor, with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
Study NCT05088434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only 60 ml of sterile 0.9% normal saline were added to the patient's own stool specimen with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
Study NCT01518725 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period